Welcome to our dedicated page for Veraxa Biotech Holding SEC filings (Ticker: VRXAW), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Veraxa Biotech Holding's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Veraxa Biotech Holding's regulatory disclosures and financial reporting.
Veraxa Biotech files an amended Form F-1 primarily to add an exhibit and provides detailed disclosure on prior unregistered equity and financing transactions around its SPAC business combination.
The company describes a share lending agreement with Xlife Sciences AG, allowing Veraxa to borrow up to 1,000,000 ordinary shares for a monthly fee of 3.5%, with subsequent share subscriptions (including 34,682 shares at CHF 47.17 and 186,744 shares at CHF 26.10) offset against liabilities under this arrangement. In the business combination, PubCo was formed, issued 100,000 ordinary shares for CHF 100,000, then effected a share split to 11,325,000 shares, increased capital by CHF 1,147,904 and issued 130,000,128 new shares to legacy Veraxa Biotech AG holders at a fixed 8.81293 exchange ratio, without cash compensation.
The disclosure also covers a May 2026 High Trail financing with a $27.5 million senior secured note and a warrant covering 2,391,305 ordinary shares at $11.50, a Lincoln Park equity purchase agreement for up to $50.0 million of ordinary shares over 24 months (with 340,910 commitment shares and a 4.99% beneficial ownership cap), a Cantor fee modification resulting in 3,500,000 ordinary shares issued as part of deferred fees, and SPAC-era founder shares and 7,665,000 private warrants exercisable at $11.50 per share.
Veraxa Biotech files Amendment No. 1 to its Form F-1 registration statement, primarily to add exhibits and provide detailed disclosure of prior unregistered securities issuances and financing arrangements related to its SPAC Business Combination and subsequent capital structure.
The company outlines Swiss-law limits on indemnification of directors and officers and notes that indemnification for Securities Act liabilities is considered unenforceable under U.S. public policy. It describes multiple private offerings of common and employee stock from 2023–2025, including issuances to investors and directors, and a share lending agreement under which Xlife Sciences AG agreed to lend up to 1,000,000 ordinary shares in exchange for a monthly fee over the agreement term.
In connection with formation of PubCo and the Business Combination, PubCo effected a share split of its CHF 100,000 initial capital into 11,325,000 shares, increased share capital by CHF 1,147,904, and issued 130,000,128 new ordinary shares to legacy Veraxa Biotech AG shareholders at an exchange ratio of 8.81293 new shares per legacy share. The filing also details a May 2026 High Trail financing involving a $27.5 million senior secured note and a warrant exercisable at $11.50 per share with 2,391,305 underlying ordinary shares, a Lincoln Park equity purchase agreement for up to $50.0 million of ordinary shares (including 340,910 commitment shares already issued), and a Cantor fee modification under which 3,500,000 ordinary shares were issued and are to be registered.
Veraxa Biotech AG, a Swiss oncology-focused biotechnology company, is registering up to 19,436,739 Ordinary Shares issuable upon exercise of Public and Private Warrants, plus up to 120,295,385 existing Ordinary Shares and 6,786,739 Private Warrants for resale by selling securityholders.
The Ordinary Shares trade on Nasdaq Global Market under VRXA and the Warrants on Nasdaq Capital Market as VRXAW; on July 30, 2026, the shares closed at $1.96 and the Warrants at $0.11. Veraxa will not receive proceeds from resales, but could receive cash from warrant exercises at $11.50 per share.
The company is an early-stage biotech with no product revenues and an accumulated deficit of CHF 66.6 million as of December 31, 2025, has never paid dividends, and flags extensive risk factors and ongoing capital needs. It qualifies as both an emerging growth company and a foreign private issuer, using Swiss corporate governance practices and IFRS reporting.
Veraxa Biotech AG, a Swiss oncology-focused biotech with antibody drug conjugate and T‑cell engager platforms, has filed a Form F‑1 to register the resale of up to 25,000,000 Ordinary Shares by Lincoln Park Capital Fund, LLC under a previously agreed equity purchase arrangement.
These shares include 340,910 commitment shares and additional shares Veraxa may sell to Lincoln Park over 24 months, supporting a facility of up to $50,000,000 in potential gross proceeds to Veraxa, although Veraxa receives no proceeds from Lincoln Park’s resales. After full issuance, Ordinary Shares outstanding would be 166,066,903.
The Lincoln Park facility is subject to a 4.99% (up to 9.99%) Beneficial Ownership Limitation. Veraxa remains an emerging growth company and foreign private issuer, following Swiss corporate governance practices, which may offer fewer protections than U.S. domestic standards. The company reports an accumulated deficit of CHF 66.6 million as it advances its oncology pipeline.
VERAXA Biotech AG reported that it has strengthened its intellectual property around its BiTAC cancer therapy platforms. In the first half of 2026, the company filed initial patent applications for its T cell engager (BiTAC-TCE) and antibody-drug-conjugate (BiTAC-ADC) technologies and related therapeutic programs, while previously granted auxiliary technology patents have cleared their opposition period.
VERAXA now has more than 50 granted owned or exclusively licensed patents in 14 countries, spread across 26 patent families, and expects recently filed applications, once granted, to protect its core technology suite through at least 2047. The BiTAC approach uses dual-component constructs and click-chemistry-based "click-to-release" payload activation to enhance tumor selectivity, safety, and manufacturability of next-generation antibody-based therapies.
Veraxa Biotech AG reported that its bispecific antibody drug conjugate program VXA-222, developed under a joint discovery alliance with OmniAb, Inc., has achieved a key technical milestone and is moving into its next collaboration phase after OmniAb concluded its discovery work.
VXA-222 applies an “AND-gate” logic, targeting two different antigens on solid tumors with a single molecule. The collaboration, established in May 2025, combines OmniAb’s transgenic antibody discovery technologies with Veraxa’s proprietary ADC linker and conjugation platform. Veraxa will now establish the bsADC lead candidate, conduct in vitro and in vivo validation, and holds exclusive rights to develop and commercialize products using OmniAb-derived antibodies, while OmniAb is entitled to a share of specified revenue. Veraxa highlights this as part of its broader strategy to advance next-generation antibody-based cancer therapeutics.
Veraxa Biotech AG reports that shareholders at the 24 July 2026 Extraordinary General Meeting approved all Board proposals, with more than 99.94% of votes cast on 102,102,301 voting shares, representing 72.20% of share capital. The amendments are intended to support long-term growth and strategic flexibility.
The Articles state share capital of CHF 1,248,634 + 50/453, divided into 141,407,813 registered shares with a par value of CHF 100/11,325 each. New authorizations add conditional share capital for equity-linked instruments, merger-related options, and employee and advisory plans, plus a capital band permitting issuance of up to 70,662,564 additional shares until 31 December 2030, in defined cases with excluded or limited subscription rights.
Governance changes include increasing the maximum Board size from five to seven and detailed rules on compensation approval, stock-based incentives and outside mandates. Veraxa also highlighted progress on its BiTAC T-cell engager program and named Carl von Halem interim CFO and Christoph Erkel, Ph.D. as Chief Scientific Officer.